Shenzhen Sciencare Pharmaceutical Co., Ltd. established in October 2017,is a modern pharmaceutical enterprise invested by multiple funds. Our research institute,base in Pingshan District, Shenzhen, has developed proprietary core sustained-release technology and materials for long-acting drugs. Our R&D pipeline focuses on addiction treatment and psychiatry, where we are a leader in the field of relapse prevention in China. In June 2024, our first product, the Naltrexone Implant for opioid relapse prevention, was approved for marketing in China by the NMPA, representing a major independently developed innovation in addiction treatment.
